|
|
|
| Clinical efficacy of Erxian decoction combined with Shengmai powder on menopausal syndrome |
| 1. Shandong Electric Power Central Hospital, Jinan, Shandong Province, 250001；2. Liaocheng Hospital of Traditional Chinese Medicine, Shandong Province |
|
|
|
Abstract To explore the clinical effect of Erxian decoction combined with Shengmai powder for treating menopausal syndrome based on estrogen level, menopausal index (KMI) score, and clinical neurological symptoms. Methods: 88 women with perimenopausal syndrome were selected and were randomly divided into two groups (44 cases in each group) by random number table from March 2021 to March 2022. The women in the control group were given routine treatment combined with progesterone, and the women in the observation group were given Erxian decoction combined with Shengmai powder treatment. The levels of serum estradiol (E2), progesterone (T), follicle-stimulating hormone (FSH) of the women in the two groups before and after treatment were measured. The curative effect, KMI, neurotransmitter, sleep quality (PSQI) score, depression situation, and adverse reactions rate of the women in the two groups were observed. Results: After treatment, the total effective rate (93.2%) of the women in the observation group was significantly higher than that (68.2%) of the women in the control group (P<0.05). The levels of E2 and T of the women in both groups had increased significantly, and the FSH level of the women in both groups had decreased significantly, and the change range of which the women in the observation group were significantly more than those of the women in the control group (P<0.05). After 1 and 2 months of treatment, KMI scores the women in both groups had decreased significantly, and which (19.52±2.27 points and 9.15±1.52 points) of the women in the observation group were significantly lower than those (25.67±3.37 points and 15.27±2.61 points) of the women in the control group. The scores of PSQI and BDI the women in both groups had decreased significantly, and which (4.16±0.52 points and 8.16±1.37 points) of the women in the observation group were significantly lower than those (6.53±1.26 points and 12.59±2.19 points) of the women in the control group. The incidence of the total adverse reactions (6.8%) of the women in the observation group was significantly lower than that (22.7%) of the women in the control group (all P<0.05). Conclusion: Erxian decoction combined with Shengmai powder for treating the women with menopausal syndrome can effectively improve their neurological symptoms, sex hormone levels, and KMI score, which can improve the clinical efficacy with less adverse reactions.
|
|
|
|
|
|
|
|
|
